Home › Burkitt Lymphoma › North Carolina › Asheville
Burkitt Lymphoma clinical trials in Asheville, NC
4 studies for Burkitt Lymphoma are looking for participants at sites in and around Asheville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Mission Hospital, Asheville
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Mission Hospital, Asheville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Mission Hospital, Asheville
Registry of Older Patients With Cancer
RecruitingObservational study
- Pardee Cancer Center, Hendersonville · 20 mi away
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Philadelphia, PA16 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- Cincinnati, OH13 studies
- New York City, NY13 studies
- Atlanta, GA12 studies
- Aurora, CO11 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Kansas City, MO10 studies
- Boston, MA10 studies
Other studies in Asheville
- Heart Failure7 studies
- Non-Small Cell Lung Cancer5 studies
- Acute Lymphoblastic Leukemia4 studies
- Acute Myeloid Leukemia4 studies
- Chronic Lymphocytic Leukemia4 studies
- Cardiovascular Disease4 studies
- Lung Cancer4 studies
- Acute Biphenotypic Leukemia3 studies
- Melanoma3 studies
- Graves Disease3 studies
- Hyperthyroidism3 studies
- Colorectal Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.